Rigel Pharmaceuticals published final 42-month follow-up from its Phase 1/2 ARROW study of pralsetinib (GAVRETO) in RET fusion-positive metastatic NSCLC in the Journal of Clinical Oncology. The company reported an overall response rate of 70% (7% complete responses, 63% partial responses) in patients with measurable disease. The update reinforces durability and a manageable safety profile, with no new safety signals and no hypersensitivity reactions in patients previously treated with immunotherapy. Three treatment-related deaths occurred in treatment-naive patients in Asia, including pneumonia (n=2) and interstitial lung disease and rhabdomyolysis (n=1 each). Investigators highlighted that responses in patients with measurable CNS metastases at baseline support broader clinical value beyond extracranial disease. Rigel positions pralsetinib as a first-line option for RET fusion-positive NSCLC, with the analysis emphasizing the importance of early biomarker testing.